Live updates: Trump administration news on tariffs | CNN Politics

White House deputy chief of staff Stephen Miller downplayed concerns over a New York Times report alleging Elon Musk's extensive drug use, pivoting to praise Musk's work as head of the Department of Government Efficiency (DOGE) in cutting government spending. The Times reported that Musk, a prominent figure in the Trump administration, allegedly used ketamine and other drugs frequently, potentially more than previously acknowledged, though it is unclear if this extended to his time in the White House. Miller declined to comment on whether Musk was drug tested during his tenure as a special government employee.

Analysis

A New York Times report alleges Elon Musk's drug use was "far more intensely than previously known" as he gained prominence within Trump's inner circle in 2024, with sources indicating frequent, sometimes daily, ketamine use, potentially mixed with other drugs. This contrasts with Musk's earlier public acknowledgement in a 2024 interview of using small, prescribed amounts of ketamine for negative moods, stating a heavy workload prevented overuse. Despite these significant allegations, White House deputy chief of staff Stephen Miller publicly stated he has "no concerns" and pivoted to praising Musk's performance as head of the Department of Government Efficiency (DOGE), crediting him with an "extraordinary job rooting out systemic waste" and saving taxpayers "billions of dollars." The New York Times noted it was unclear if the alleged drug use extended to Musk's tenure at the White House, and Miller declined to clarify whether drug testing was a requirement for Musk's special government employee position. The situation underscores a notable divergence between serious personal conduct allegations published by a prominent media outlet and a strong governmental endorsement of Musk's work. Market signals indicate a neutral sentiment overall (0.0 score) and specifically for New York Times Co. (NYT), with a very low market impact score (0.05), suggesting that current investor reaction to this specific development is muted, framing it primarily as a political and governance issue rather than an immediate, broad financial market event.

Key Decisions for Investors

• Investors should note the White House's robust defense of Elon Musk's governmental contributions, which currently appears to be mitigating the immediate political or direct market impact of the New York Times' allegations regarding his reported drug use.
• It is prudent to monitor for any further developments, corroboration, or refutation of these allegations, as sustained scrutiny on Musk's conduct could introduce reputational risks, potentially influencing perceptions of his leadership, even if the current market impact score is low.
• Given the neutral sentiment for New York Times Co. (NYT) associated with this report, its role as the investigative publisher is not indicated as a significant immediate driver for its stock, though the story highlights its continued activity in high-profile reporting.